Abstract It has been proposed that rare variants within the double strand break repair genes CHEK2, BRIP1 and PALB2 predispose to breast cancer. The aim of this study was to evaluate the prevalence of these variants in an Irish breast cancer cohort and determine their contribution to the development of breast cancer in the west of Ireland. We evaluated the presence of CHEK2_1100delC variant in 903 breast cancer cases and 1,016 controls. Six previously described variants within BRIP1 and five within PALB2 were screened in 192 patients with early-onset or familial breast cancer. Where a variant was evident, it was then examined in the remainder of our 711 unselected breast cancer cases. CHEK2_1100delC was found in 5/903 (0.5%) breast cancer cases compared to 1/1016 (0.1%) controls. One mutation at BRIP1 (2392 C[T) was identified in the early-onset/familial cohort. Examination of this variant in the remainder of our cohort (711 cases) failed to identify any additional cases. None of the previously described PALB2 variants were demonstrated in the early-onset/familial cohort. We show evidence of CHEK2_1100delC and BRIP1 2392 C[T within the Irish population. CHEK2_1100delC and BRIP1 mutations incidence in Ireland is similar to that found in other unselected breast cancer cohorts from northern European countries. We found no evidence to suggest that PALB2 mutation is an important breast cancer predisposition gene in this population.
Introduction
Breast cancer has long been known to have a significant genetic component; females with an affected first-degree relative carry an approximately 1.8 increased relative risk compared with the general population [1] . Mutations in the high-penetrance predisposition genes BRCA1 and BRCA2 account for less than 20% of familial breast cancer [2] . BRCA1 and BRCA2 have roles in the double strand break repair (DSBR) pathway and DSBR genes have been screened for mutations in breast cancer cases without BRCA1 or BRCA2 mutations. Rare variants in three of these genes-CHEK2, BRIP1 and PALB2-with allele frequencies of 0.4, 0.1 and less than 0.1%, respectively have been associated with breast cancer risk [3] . These variants demonstrate moderate penetrance with regard to breast cancer susceptibility with an increased relative risk of 2-4-fold [4] [5] [6] .
The most extensively studied of the three breast cancer genes is CHEK2. Although many mutations in CHEK2 have been described, the commonest in northern Europeans countries is CHEK2_1100delC with an incidence of 0.7% in unselected breast cancer and 2.1% in familial breast cancer [4] . CHEK2_1100delC is less common in Mediterranean and Asian countries [7] [8] [9] . Pharoah et al. estimated the absolute risk of breast cancer by age 70 in carriers of CHEK2_1100delC to be 13% compared to 5.7% in non-carriers, while in first-degree relatives it is responsible for 1.4% of the excess risk [10] .
Seal et al. identified six truncating mutations within the Fanconi anaemia J gene BRIP1, which were estimated to confer a twofold increased relative risk of breast cancer in monoallelic carriers [5] . BRIP1 mutations were present in 9/1,212 breast cancer cases negative for BRCA1/2 mutations compared with 2/2,081 controls (p = 0.003) [5] . A non-sense mutation 2392C[T (R798X) accounted for the majority of mutations in this gene. These findings have not, however, been replicated in more recent studies [11] [12] [13] [14] [15] [16] [17] [18] [19] .
Study of BRCA2 revealed an associated gene PALB2 (also known as FANCN), in which biallelic mutations cause Fanconi anaemia. Rahman et al. screened PALB2 in 923 familial breast cancer patients and identified five truncating mutations, which were estimated to confer a 2.3-fold increased risk of breast cancer [6] . Additional rare novel truncating mutations have also been discovered by other groups [20, 21] . The Finnish founder mutation identified by Erkko et al., c.1592delT, has been estimated to confer a lifetime risk of breast cancer equivalent to BRCA2 mutation carriers [22, 23] . The possibility of specific PALB2 variants conferring high penetrance in breast cancer was further proposed by Tischkowitz et al. following their discovery of a truncating mutation PALB2 229delT [24] . These findings suggest that the relative risk of developing breast cancer previously attributed to PALB2 mutations may have been underestimated by Rahman et al.
Gunnarsson et al., however, found no role for PALB2 in breast cancer susceptibility in an Icelandic cohort [25] .
Although still at an early stage in the investigation of these moderate-penetrance variants, there is evidence of geographical variation in their frequencies. The existence of clinically relevant founder mutations in some populations is possible. The west of Ireland is geographically isolated from the rest of Europe and, while it shares some of its ancestry with the UK, it has experienced less inward demographic movement [26] and is relatively homogeneous. The aims of this study were to investigate whether known variants in CHEK2, BRIP1 and PALB2 contribute to breast cancer susceptibility in the west of Ireland.
Methods
Breast cancer patients and controls from the west of Ireland were collected with appropriate ethical approval as part of the Breast cancer in Galway Genetics Study (BIGGS). Cases were not selected with regard to family history of breast or ovarian cancer, personal history of ovarian cancer, the presence of a contralateral breast cancer or other second primary cancer. All controls were from west of Ireland lineage (as were cases) and comprised women over the age of 60, with no self-reported personal history of any cancer and no family history of breast or ovarian cancer. From this cohort of unselected breast cancer cases, 192 cases were identified as being at relatively high risk of having an inherited predisposition to breast cancer (cases presenting at\42 years old or\55 years old with a history of breast cancer in one or more first or second degree relative). DNA was purified from 10-ml samples of blood using the Chemagic Magnetic Separation Module (Chemagen, Baesweiler, Germany) using the manufacturer's reagents. Primers (Supplementary Data, Table 1 ) were designed to amplify a DNA fragment of 167 base pairs across CHEK2_1100delC and Genotyper software (ABI) was used to size the fragment. Genotyping was performed in 96-well format and optimised using a known CHEK2_1100delC heterozygous control on each plate. Samples with 2 bands and any equivocal results were sequenced to confirm the result using the ABI 3100 automated sequencer and sequence analysis software (Applied Biosystems, CA), Fig. 1 .
Truncating mutations in BRIP1 and PALB2 previously identified in a UK cohort by Seal et al. and Rahman et al., Table 1 , were analysed by direct sequencing in the earlyonset/familial subset. Primers are listed in Supplementary Data, Table 1 . Where a variant was identified, it was subsequently genotyped in the remaining 711 breast cancer patient samples using the KASPar SNP genotyping system (KBiosciences).
Meta-analysis data were combined using the MantelHaenszel method. All statistical analyses were undertaken using STATA 9.2 (Stata Corp, College Station, TX).
Results
The pathological characteristics of the whole cohort are described elsewhere [27] . From this cohort of unselected breast cancer cases, 192 cases were identified as being at relatively high risk of having an inherited predisposition to breast cancer (cases presenting at \42 years old or \55 years old with a history of breast cancer in one or more first or second degree relative). Histological information was available in all of these cases and is summarized in Table 2 . are summarized in Table 3 . One CHEK2_1100delC mutation carrier was diagnosed at 60 and had a family history of breast cancer on her paternal side, with an aunt, two-first cousins and grandmother being affected. The remaining four CHEK2_1100delC mutation carriers had no family history of breast cancer, but two had a family history of leukaemia. The control carrier was an 82-year-old female with no personal or family history of cancer.
Analysis of CHEK2
Population variation is evident in the prevalence of CHEK2_1100delC, with the highest incidence reported in Dutch cohorts (3.8% cases and 1.6% controls) and a negative association with breast cancer susceptibility demonstrated in a Spanish cohort [4, 7] . We have combined our data with that of previous meta-analyses carried out by the CHEK2 Breast Cancer Case-Control Consortium and Weischer et al. [4, 28] 
BRIP1 analysis
BRIP1 mutation (2392 C[T, Fig. 3 ) was found in 1/192 (0.5%) of the early-onset/familial patients. This patient was diagnosed with ductal breast cancer at age 53 and had a sister affected at 55 years of age. We then examined this variant, BRIP1 2392 C[T, in the remainder of our cohort of 711 cases, but none was found. None of the other BRIP1 mutations previously found by Rahman et al. were present in the early-onset/familial series and were therefore not screened for in the remaining cases. Table 4 summarizes the findings from other studies. Very few studies have looked for BRIP1 mutations and due to the small numbers a meta-analysis is not possible. However, there was no evidence of heterogeneity between studies (p = 0.145, heterogeneity v 2 test) suggesting BRIP1 is a rare breast cancer predisposition gene. The finding of one BRIP1 mutation in our subset of early-onset/familial breast cancer and no other mutations in the whole cohort is consistent with the population frequency of 0.1% previously estimated. Table 5 . We performed a meta-analysis of these studies (studies with the same controls were considered together) which showed an overall odds ratio of 8.92 (95% CI 3.4-23.4), Fig. 4 . There was no evidence of heterogeneity between studies (p = 0.11, heterogeneity v 2 test).
Discussion
We have shown an increased risk of breast cancer with CHEK2_1100delC mutations in the west of Ireland, similar to that found in other northern and central European countries. The recent meta-analysis of CHEK2_1100delC by Weischer et al. [28] , demonstrated that unselected and early-onset cases had a similar relative risk of breast cancer (OR 2.7, 95% CI 2.1-3.4; OR 2.6, 95% CI 1.3-5.5, respectively), however, the familial cases (defined as at least one-first and one-second degree relative with breast cancer, a male relative with breast cancer, or at least one patient case of female breast cancer and one patient case of ovarian cancer among relatives) had a much higher relative risk (OR 4.8, 95% CI 3.3-7.2, p \ 0.0001). We did not see this in our series, in contrast our subset of familial/earlyonset cases showed no CHEK2_1100delC mutation. However, this is likely to be due to the small numbers and the inclusion of early-onset breast cancers in our 'highrisk' group (Table 2) . To our knowledge this is the first study to replicate the identification by Seal et al. of the BRIP1 2392 C[T mutation. We analysed those variants in BRIP1 identified by Seal et al. due to the relative homogeneity between the Irish and UK populations [5] . The BRIP1 2392 C[T mutation was the most common mutation found by Seal et al., accounting for five of the nine mutations they detected. It has not been demonstrated in any population outside Ireland or the UK, suggesting it may be specific to these populations. Like CHEK2_1100delC, there appears to be considerable population variation in the incidence of PALB2 mutations, with a particularly high incidence in Finland (1592delT) and very few in the Icelandic and Irish populations. However, the Icelandic study [25] and our study did not screen the whole gene for novel mutations, and it is therefore possible that these populations contain as yet unidentified mutations.
In conclusion, this is the first study of proposed moderate-penetrance breast cancer susceptibility variants in an Irish cohort of breast cancer patients. CHEK2_1100delC was carried by 0.5% of cases compared with 0.1% of controls, a similar prevalence to that found in the United Kingdom. BRIP and PALB2 mutation appear to be rare in the Irish breast cancer population as they are in other populations, but mutation screening of these genes in a large familial Irish cohort will be required to fully establish what possible role mutations in these genes play in familial breast cancer in Ireland.
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